MCL1 and breast cancer: PLA confirmed increased Mcl-1 activity in ERα+ breast cancer cells treated with ABT-263, while showing that Mcl-1 activity was diminished in cells treated with RAD001, even in those cells treated with ABT-263 (Figure 3B–3C).